-2%
Gliclazide is a second-generation sulfonylurea that lowers blood glucose primarily by stimulating insulin release from pancreatic beta cells. It enhances calcium transport within these cells, promoting insulin secretion, and also helps reduce hepatic glucose production.
Glix MR is an oral antidiabetic medicine containing gliclazide, a sulfonylurea. It is used to control blood glucose in adults with type 2 diabetes mellitus when diet, exercise, and weight management alone are not sufficient.
The dose of Glix MR should be individualized according to blood and, when necessary, urine glucose levels.
For the modified-release formulation, the usual dosage is 30–120 mg once daily, taken at breakfast. The tablet should be swallowed whole with water and should not be crushed or chewed. A meal should always be eaten after taking the medicine.
Changes in weight, diet, physical activity, stress, or improvement in blood glucose control may require dose adjustment.
When gliclazide is used together with medicines such as metformin, alpha-glucosidase inhibitors, thiazolidinediones, DPP-4 inhibitors, GLP-1 receptor agonists, or insulin, the doctor will determine the appropriate dose of each medicine.
If a dose is missed, take the next dose at the regular time. Do not take a double dose to compensate for the missed dose.
Glix MR should not be discontinued without medical advice, as stopping treatment may cause blood glucose levels to rise.